Genetics in Medicine

An Official Journal of the ACMG

ARTICLE

Genotypic and phenotypic spectrum of infantile liver failure due to pathogenic *TRMU* variants

ARTICLE INFO

ABSTRACT

Purpose: This study aimed to define the genotypic and phenotypic spectrum of reversible acute liver failure (ALF) of infancy resulting from biallelic pathogenic *TRMU* variants and determine the role of cysteine supplementation in its treatment.
Methods: Individuals with biallelic (likely) pathogenic variants in *TRMU* were studied within an international retrospective collection of de-identified patient data.
Results: In 62 individuals, including 30 previously unreported cases, we described 47 (likely) pathogenic *TRMU* variants, of which 17 were novel, and 1 intragenic deletion. Of these 62 individuals, 42 were alive at a median age of 6.8 (0.6-22) years after a median follow-up of 3.6 (0.1-22) years. The most frequent finding, occurring in all but 2 individuals, was liver involvement. ALF occurred only in the first year of life and was reported in 43 of 62 individuals; 11 of whom received liver transplantation. Loss-of-function *TRMU* variants were associated with poor survival. Supplementation with at least 1 cysteine source, typically N-acetylcysteine, improved survival significantly. Neurodevelopmental delay was observed in 11 individuals and persisted in 4 of the survivors, but we were unable to determine whether this was a primary or a secondary consequence of TRMU deficiency.
Conclusion: In most patients, TRMU-associated ALF was a transient, reversible disease and cysteine supplementation improved survival.

Introduction

The sudden onset of liver failure in an individual with no previous history of chronic hepatic dysfunction is termed acute liver failure (ALF). Knowledge of the underlying cause is key for decision-making about appropriate treatment, especially with regards to liver transplantation (LTX). Infections and inherited metabolic disorders (IMD) are common causes of ALF and are typically confirmed using conventional diagnostic strategies for viral agents or metabolite screening. Increasingly, next-generation sequencing techniques have become the first line diagnostic screening test, and they bridge the diagnostic gap in >30% of the cases that remain unsolved after the application of conventional diagnostics.[1]

TRMU is a nuclear gene encoding a crucial protein for mitochondrial translation, transfer RNA (tRNA) 5-methyl-aminomethyl-2-thiouridylate methyltransferase (TRMU), which catalyzes the important post-translation modification (thiolation) of mitochondrial tRNAs. Biallelic variants in *TRMU* underlie TRMU deficiency and were first described in association with infantile ALF.[2] In that original patient cohort of 13 individuals, 4 died of ALF; however, the other 9 patients survived and showed no further hepatological or neurologic issues over the next 14 years of follow-up. A

Georg F. Vogel, Yael Mozer-Glassberg, and Yuval E. Landau contributed equally.

*Correspondence and requests for materials should be addressed to Georg F. Vogel, Department of Paediatrics I, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria. *Email address:* georg.vogel@i-med.ac.at

A full list of authors and affiliations appears at the end of the paper.

further 23 cases have since been reported in the literature,[3-16] with TRMU deficiency now termed as "transient, infantile liver failure" (OMIM 613070).

It is hypothesized that TRMU uses cysteine as the substrate for thiolation, and cysteine might be a conditionally essential amino acid in the first months of life.[17] Therefore, L-cysteine or N-acetylcysteine (NAC) have been supplemented in individuals with TRMU deficiency, and anecdotal case reports showed beneficial effects.[11,15] However, many individuals with TRMU deficiency are reported to require LTX.[5,15]

TRMU deficiency is a disorder of the mitochondrial transcript processing and mitochondrial tRNA modification category (international classification of IMD[18]). Consequently, the synthesis of mitochondrial DNA-encoded proteins is impaired and mitochondrial respiratory chain function is severely compromised, resulting in disease. Many mitochondrial diseases are characterized by multiorgan involvement, including severe and progressive neurologic deterioration.

Hence, at least 4 important questions arise when a diagnosis of TRMU deficiency is made in an infant. What is the further course of disease? Is other organ involvement, especially neurologic involvement, to be expected? Will LTX be needed and when should it be performed? Is supplementation with a cysteine source beneficial and how long should this be continued?

In this article, we present a multicenter study of 62 patients with biallelic *TRMU* variants identified via international collaboration and literature review and seek to answer these questions in an evidence-based manner.

Material and Methods

Study design and data acquisition

Individuals were included based on an international retrospective collection of de-identified data. Inclusion criteria were presence of rare biallelic variants in *TRMU* classified as likely pathogenic or pathogenic according to the American College of Medical Genetics and Genomics guidelines.[19] Eligible individuals were identified via literature review (eg, PubMed using the search term "TRMU") and international collaborations. If individuals had been published previously, the respective authors were contacted for an update, if that was not received, only published data were included. All data were retrieved via standardized proformas agreed by participating centers.

For phenotyping, the following variables were analyzed within this study: individual's genetic ancestry, sex, age at last assessment, and clinical status. In addition, detailed data on liver disease, laboratory values, and clinical features of the main organ systems involved were scrutinized and recorded according to Human Phenotype Ontology terminology.[20]

Regarding standards of evidence for therapeutic studies, we used the grading system from the Centre for Evidence-Based Medicine (http://www.cebm.net, eg, level 1c = "All or None" which means [prolongation of] survival with therapy).

American College of Medical Genetics and Genomics classification

The meta tool REVEL that combines SIFT, PolyPhen-2, HVAR and HDIV, LRT, Mutation Taster, Mutation Assessor, FATHMM v2.3, and VEST 3.0 was used for PP3 scoring. If the result of the REVEL prediction was pathogenic, 4 points in PP3 were given. All analyzed variants were identified to be either pathogenic or uncertain using REVEL. PP4 was applied to all variants because of the highly specific clinical features, with the exception of p.(Gly272Asp) in patient 52 (no liver involvement reported). Four points were given for PS3 if tRNA metabolism was analyzed and altered. Two points for PS3 were given if OXPHOS enzyme activity was reduced. Criteria for PP5 were not met. For all variants the following reference sequences were used: NM_018006.5, NP_060476.2 and NC_000022.11.

In silico modeling of *TRMU* missense variant pathogenicity scores

To assess the predicted effect of missense variants, commonly used prediction scores (M-CAP v.3.5a and REVEL v.3.5a[21-23]) were annotated for all biologically possible *TRMU* missense variants and mapped onto a linearized representation of the TRMU protein, as previously demonstrated.[24,25] We generated all biologically possible base substitutions in the *TRMU* coding sequence (transcript: NM_018006.5) and used the Mutalyzer Position Converter to match the resulting variant call format file to the GRCh37/hg19 reference genome. Scores were annotated using the Ensembl variant effect prediction tool. A generalized additive model was built using the *geom_smooth* function of the R (R Core Team, Vienna, Austria) ggplot2 package to plot a smoothened line and CI.

Statistics and software

Kaplan-Meier estimators were calculated using R survival package. Bar and density plots were generated using the R ggplot2 package. Schematics and figures were compiled using Illustrator CS6 (Adobe).

Results

Study population

A total of 62 individuals (24 female, 9 sex not available [NA]) from 56 families residing in 18 countries were

included, of whom 32 were previously published[2-16] (Tables 1 and 2). For 13 individuals, solely the published data were available (L-TRMU-49 to L-TRMU-62[2,4,8,9,13,16]).

Of note, we did not include 1 previously published individual with compound heterozygosity for variants c.697C>T, p.(Leu233Phe) and c.28G>T, p.(Ala10Ser) (benign, found 1230 times in homozygous state in Genome Aggregation Database).[2] Data pertaining to respiratory chain enzyme activities, serum amino acid levels, organic acid profiles, and further laboratory findings are documented in Supplemental Table 1.

Genetics

A total of 47 different variants were identified; of these, 17 have not been reported previously (Table 1, Figure 1A). In 2 siblings (TRMU-12 and TRMU-13), a deletion encompassing more than 1 exon in phase with a recognized missense *TRMU* variant was detected.

Variants were distributed throughout the gene (Figure 1A) with an increased density in the catalytic domain near the interaction site with the target base in tRNA and in the β-barrel (Figure 1B). The most frequent variants were the missense variants c.835A>G, p.(Val279Met) and c.229T>C, p.(Tyr77His) detected in 16 and 13 individuals, respectively. As expected, variants showed comparable REVEL scores throughout the gene with fewer variants in the C-terminal region of the protein (Figure 1C). The 17 loss-of-function (LoF) variants and the intragenic deletion predicted to lead to loss of protein were detected at least in monoallelic state in 23 individuals. Presence of a LoF variant strongly affected on overall individual survival (P = .0089) (Figure 1D). Overall survival did not differ between individuals having a LoF variant in 1 allele only and those having it in both the alleles. (P = .6) (Supplemental Figure 1A).

Phenotypic spectrum

The cohort comprised 62 individuals; of whom, 42 were alive at the time of data collection (median age = 6.8 years, range = 0.6-22.5 years, interquartile range [IQR] = 8.2 years). The median age of death was 3 (range = 0.1-8, IQR = 2) months. First symptoms were recognized at a median age of 2 (IQR = 3) months, and the genetic diagnosis was made at a median age of 6 (IQR = 13.8) months. In 2 individuals, the diagnosis was made prenatally, both alive at inclusion, and in 9 individuals post mortem. The total duration of follow-up of the cohort was 302 years, individually ranging from 0.1 to 22 (median = 3.6, IQR = 2.18) years.

The most frequent finding in all but 2 individuals (60/62, 1 NA) was liver involvement (HP:0001392). Lactic acidosis (HP:0003128, 45/62), abnormal body weight (HP:004323, 39/62, 8 NA), emesis and/or diarrhea (HP:0011458, 29/62,

8 NA), abnormality of the nervous system (HP:0000707, 26/62, 5 NA), muscular hypotonia (HP:0001252, 22/62, 5 NA), and abnormal growth (HP:0001507, 21/62, 7 NA) were further commonly reported symptoms (Figure 1E). Cause of death was most frequently reported to be multiple organ failure (8/20) or hepatic failure (8/20) (Figure 2B).

The detailed metabolic findings in blood and urine, as well as respiratory chain enzyme activities analyzed in available tissues, did not show a specific pattern and can be found in Supplemental Table 1.

Oral supplementation of a cysteine source was reported in 40% of the individuals (25/62), with NAC being most frequently used (19/25) at a median dosage of 150 (IQR = 62.5) mg/kg/d. The overall individual survival was significantly better (P = .0052) in individuals using any kind of cysteine supplementation than in the ones without (Figure 2A). This was even more significant (P = .0033) for the subgroup of 22 individuals with LoF variants (Supplemental Figure 1B).

Abnormalities of the liver (HP:0001392)

The most common hepatic feature reported was elevated hepatic transaminases (HP:0002910, 52/62, 5 NA). ALF (ORPHA:90062), defined according to a recent consensus definition (ie, acute onset of liver disease without evidence of chronic liver disease and biochemical evidence of severe liver injury: prothrombin time of ≥15 seconds or international normalized ratio of ≥1.5 with evidence of hepatic encephalopathy, or prothrombin time of ≥20 seconds or international normalized ratio of ≥2 with or without encephalopathy[26]), was reported in 43 of 62 (2 NA) individuals.

Further hepatic involvement included jaundice (HP:0000952, 34/62, 8 NA) and hepatomegaly (HP:0002240, 14/62, 4 NA) (Figure 2C). ALF episodes were reported earliest at age 2 weeks, peaking between 1 and 5 months but were not reported after the first year of life (Figure 2D). Of 43 individuals with episodes of ALF, 33 had a single episode; although, recurrence of up to 5 episodes was reported (Figure 2E). Hepatic encephalopathy was reported in 13 individuals.

A total of 11 individuals received LTX, which was performed during the first episode of ALF in 4 individuals and on recurrent episodes in 6 individuals. Of note, 1 individual who received LTX because of hepatoblastoma at age 11 years was excluded from this analysis. Median age at LTX was 4 (IQR = 1.75, range = 3-10) months. There was no difference in overall individual survival based on LTX (P = .079) (Figure 2F). Two individuals died despite LTX: 1 during surgery because of variceal bleeding and the other one shortly after LTX because of multiple organ failure. Despite its benefit on overall individual survival, supplementation therapy (eg, NAC) did not avert LTX (native liver survival, P = .24) (Figure 3A). Analysis of hepatic biopsies, performed in 31 individuals, revealed fibrotic/cirrhotic

Table 1 Overview of *TRMU* variants of all individuals in this study

No.	Individual	Nucleotide Change NM_018006.5	Predicted Protein Change NP_060476.2	Genomic Position: NC_000022.11, hg38	LoF	ACMG Rating	Details of ACMG Rating	gnomAD Allele Frequency	Reference
1	**TRMU-16**	**c.2T>C**	**p.(Met1?)**	**46335766T>C**	**Yes**	**PTH**	**PVS1, PS1, PM2, PP4**	**0**	
2	L-TRMU-54, L-TRMU-55, L-TRMU-59	c.2T>A	p.(Met1?)	46335766T>A	Yes	PTH	PVS1, PS3, PM2, PP4	0	Zeharia et al,[2] Sala-Coromina et al[16]
3	L-TRMU-57	c.34_35dup	p.(Gly13ProfsTer13)	46335798_46335799dup	Yes	PTH	PVS1, PM2, PP4	0	Qin et al[13]
4	TRMU-15	c.37_48dup	p.(Gly13_Asp16dup)	46335801_46335812dup		LPTH	PM2, PM4, PP4	0.00003575	Murali et al[15]
5	TRMU-08, TRMU-38	c.40G>A	p.(Gly14Ser)	46335804G>A		PTH	PS3, PM1, PM2, PP3, PP4	6.47E-5	Zeharia et al[2]
6	**TRMU-07**	**c.44T>G**	**p.(Val15Gly)**	**46335808T>G**		**PTH**	**PM1, PM2, PP3, PP4**	**0**	
7	TRMU-30, TRMU-31	c.117G>A	p.(Trp39Ter)	46337813G>A	Yes	PTH	PVS1, PM2, PP1, PP4	0	Soler-Alfonso et al,[11] Murali et al[15]
8	L-TRMU-58	c.162_163del	p.(Cys54Ter)	46337858_46337859del	Yes	PTH	PVS1, PS3, PM2, PP4	0	Sala-Coromina et al[16]
9	TRMU-19, TRMU-33, TRMU-34, TRMU-35, TRMU-36, TRMU-37, TRMU-47, TRMU-48; L-TRMU-49, L-TRMU-50, L-TRMU-51, L-TRMU-61, L-TRMU-62	c.229T>C	p.(Tyr77His)	46337925T>C		PTH	PS3, PM2, PM3, PP3, PP4	0	Zeharia et al,[2] Gil-Margolis et al[9]
10	L-TRMU-57	c.244T>G	p.(Phe82Val)	46337940T>G		PTH	PS1, PM2, PM3, PP3, PP4	0	Qin et al[13]
11	TRMU-14	c.246C>G	p.(Phe82Leu)	46337942C>G		LPTH	PS1, PM2, PP4	0	Murali et al[15]
12	TRMU-05	c.248+1G>A	p.(?)	46337945G>A	Yes	PTH	PVS1, PS3, PM2, PP4	0	Gaignard et al[5]
13	TRMU-22, TRMU-23, TRMU-27, TRMU-46	c.287A>G	p.(Asn96Ser)	46343300A>G		PTH	PM1, PM2, PP3, PP4	0	Taylor et al[6]
14	L-TRMU-60	c.304A>G	p.(Asn102Asp)	46343317A>G		PTH	PS3, PM2, PP3, PP4	0	Indolfi et al[8]
15	**TRMU-40**	**c.339T>G**	**p.(Tyr113Ter)**	**46343352T>G**	**Yes**	**PTH**	**PVS1, PM2, PP4**	**0**	
16	TRMU-42	c.383A>G	p.(Tyr128Cys)	46346449A>G		PTH	PM2, PP3, PP4	0	Nicastro et al[10]
17	L-TRMU-59	c.491del	p.(Leu164ProfsTer22)	46350303-T	Yes	PTH	PVS1, PS3, PM2, PP4	0	Sala-Coromina et al[16]
18	L-TRMU-53	c.500_510del	p.(Ala167GlufsTer36)	46350312_46350322del	Yes	PTH	PVS1, PS3, PM2, PP4	0	Zeharia et al[2]
19	**TRMU-27**	**c.521C>T**	**p.(Thr174Ile)**	**46350333C>T**		**PTH**	**PM2, PP3, PP4**	**0**	

Table 1 Continued

No.	Individual	Nucleotide Change NM_018006.5	Predicted Protein Change NP_060476.2	Genomic Position: NC_000022.11, hg38	LoF	ACMG Rating	Details of ACMG Rating	gnomAD Allele Frequency	Reference
20	TRMU-14	c.525_527del	p.(Phe176del)	46350337_ 46350339del		LPTH	PM2, PM4, PP4	0.00001193	Murali et al[15]
21	**TRMU-24**	**c.530T>A**	**p.(Leu177His)**	**46350342T>A**		**PTH**	**PM2, PP3, PP4**	**0**	
22	**TRMU-44**	**c.581del**	**p.(Gly194AspfsTer2)**	**46350388-G**	**Yes**	**PTH**	**PVS1, PM2, PP4**	**0.00002475**	
23	TRMU-01	c.589A>C	p.(Lys197Gln)	46350401A>C		PTH	PM2, PP3, PP4	0	Kerr et al[12]
24	**TRMU-44**	**c.611C>T**	**p.(Ala204Val)**	**46350423C>T**		**PTH**	**PM2, PM3, PP3, PP4**	**0**	
25	**TRMU-40**	**c.646_648del**	**p.(Lys216del)**	**46350458_ 46350460del**		**LPTH**	**PM2, PM3, PM4, PP4**	**0**	
26	TRMU-11	c.649G>A	p.(Glu217Lys)	46350461G>A		PTH	PS3, PM2, PP3, PP4	0	Gaignard et al[5]
27	**TRMU-39, TRMU-41**	**c.653G>T**	**p.(Ser218Ile)**	**46352122G>T**		**PTH**	**PM2, PP3, PP4**	**0**	
28	**TRMU-10**	**c.664T>G**	**p.(Cys222Gly)**	**46352133T>G**		**PTH**	**PM1, PM2, PP3, PP4**	**0**	
29	**TRMU-45**	**c.671T>G**	**p.(Ile224Ser)**	**46352140T>C**		**PTH**	**PM2, PP3, PP4**	**0**	
30	TRMU-30, TRMU-31; L-TRMU-58	c.680G>C	p.(Arg227Thr)	46352149G>C		PTH	PS3, PM2, PM3, PP1, PP4	0	Soler-Alfonso et al,[11] Murali et al,[15] Sala-Coromina et al[16]
31	TRMU-06	c.697C>T	p.(Leu233Phe)	46352166C>T		LPTH	PM2, PP4	0	Zeharia et al[2]
32	TRMU-47, L-TRMU-49	c.706-1G>A	p.(?)	46352263G>A	Yes	PTH	PVS1, PS3, PM2, PP4	0.000003976	Zeharia et al[2]
33	TRMU-32	c.711dup	p.(Gln238AlafsTer14)	46352269–G	Yes	PTH	PVS1, PS3, PM2, PP4	0	Schara et al[3]
34	L-TRMU-52	c.815G>A	p.(Gly272Asp)	46353809G>A		LPTH	PS3, PM2, PP3	0	Zeharia et al[2]
35	**TRMU-20**	**c.827C>T**	**p.(Pro276Leu)**	**46353821C>T**		**PTH**	**PM2, PP3, PP4**	**0**	
36	TRMU-02, TRMU-03, TRMU-04, TRMU-05, TRMU-11, TRMU-17, TRMU-25, TRMU-26, TRMU-28, TRMU-29, TRMU-42, TRMU-43, TRMU-45; L-TRMU-53, L-TRMU-56, L-TRMU-60	c.835G>A	p.(Val279Met)	46353829G>A		PTH	PS3, PM2, PM3, PP3, PP4	0	Zeharia et al,[2] Uusimaa et al,[4] Gaignard et al,[5] Grover et al,[7] Indolfi et al[8]
37	**TRMU-08**	**c.878C>T**	**p.(Pro293Leu)**	**46355448C>T**		**LPTH**	**PM2, PP4**	**0**	
38	**TRMU-03**	**c.936G>A**	**p.(Trp312Ter)**	**46355506G>A**	**Yes**	**PTH**	**PVS1, PM2, PP4**	**0**	
39	**TRMU-18, TRMU-28**	**c.954dup**	**p.(Ala319ArgfsTer87)**	**46355522–C**	**Yes**	**PTH**	**PVS1, PM2, PP4**	**0.00004395**	
40	**TRMU-21**	**c.1005C>G**	**p.(His335Gln)**	**46355575C>G**		**PTH**	**PM1, PM2, PP3, PP4**	**0**	
41	TRMU-02	c.1041_1044del	p.(Asn347LysfsTer7)	46356012_ 46356015del	Yes	PTH	PVS1, PM2, PP4	0	Grover et al[7]
42	TRMU-09, TRMU-24, TRMU-32, TRMU-39, TRMU-41	c.1073_1081dup	p.(Gln358_Val360dup)	46356044_ 46356052dup		PTH	PS3, PM2, PM3, PM4, PP4	0.00002477	Schara et al[3]
43	TRMU-01	c.1081C>T	p.(Arg361Cys)	46356052C>T		LPTH	PM2, PP4	3.23E-5	Kerr et al[12]

Table 1 Continued

No.	Individual	Nucleotide Change NM_018006.5	Predicted Protein Change NP_060476.2	Genomic Position: NC_000022.11, hg38	LoF	ACMG Rating	Details of ACMG Rating	gnomAD Allele Frequency	Reference
44	TRMU-12, TRMU-13	c.1084G>A	p.(Ala362Thr)	46356055G>A		PTH	PS3, PM2, PM3, PP1, PP4	0	Murali et al[15]
45	L-TRMU-56	c.1102-3C>G	p.(?)	46356839C>G	Yes	PTH	PS3, PM2, PP4	0.000007093	Uusimaa et al[4]
46	**TRMU-09**	**c.1108G>A**	**p.(Val370Met)**	**46356848G>A**		**LPTH**	**PM2, PP4**	**0**	
47	TRMU-04, TRMU-15	c.1142G>A	p.(Gly381Glu)	46356882G>A		LPTH	PM2, PP4	0	Murali et al[15]
	TRMU-12, TRMU-13	del 22q13.31 46,730,453–4,673,227			Yes				Murali et al[15]

The version number for each transcript is omitted, however it can be cross referenced from Table 2. Variants presented in bold are novel. Four points for PP4 were given for all cases except for patient 52 (no liver involvement reported) because the clinical features were highly characteristic for all patients included in the study. Four points were given for PS3 if transfer RNA metabolism was analyzed and altered. Two points for PS3 were given if OXPHOS enzyme activity was reduced. If the result of the REVEL prediction was pathogenic, 4 points were given in PP3. The following reference numbers were used for all variants: NM_018006.5, NP_060476.2 and NC_000022.11.

ACMG, American College of Medical Genetics and Genomics; bp, basepair; gnomAD, Genome Aggregation Database; LoF, loss of function; LPTH, likely pathogenic; PTH, pathogenic.

changes of hepatic parenchyma as the most frequent finding (62%) followed by macrovesicular steatosis (41%), cholestatic changes (41%), and microvesicular steatosis (43%) (Figure 3B).

Nonhepatic phenotypic spectrum including neurodevelopmental outcome

Further commonly reported symptoms of individuals with TRMU deficiency were failure to thrive (HP:0001399, 39/62, 8 NA), neurodevelopmental delay (HP:0000707, 26/62, 9 NA), muscular hypotonia (HP:0001252, 22/62, 5 NA), growth retardation (HP:0001510, 21/62, 7 NA), and motor delay (HP:0001270, 5/62, 4 NA) (Figure 3C). Neurodevelopmental delay resolved in 11 of 26 and persisted in 4 of 26 individuals to varying extents (3/4 severe, 1/4 only motor delay persisted), another 9 of 26 individuals were reported deceased, and 2 lost to follow-up (Figure 3D). In the study cohort, individuals were also reported to develop encephalopathy (HP:000129, 6/62, 4 NA), cardiomyopathy (HP:0001638, 5/62, 4 NA, follow-up: 1/5 resolved, 1/5 mild left ventricular dilatation, 3/5 unknown because they deceased), epileptic seizures (HP:0001250, 4/62, 4 NA), and further rare presentations (Figure 3E).

Discussion

The list of monogenetic diseases associated with pediatric ALF is expanding owing to the increasing availability and applicability of next-generation sequencing technologies. Within this patient group, pathogenic variants in genes pivotal for mitochondrial function are separately recognized, because ALF can be the first symptom of a future multiorgan disease. Particularly, the risk of coexisting cardiomyopathy and cerebral involvement must be excluded when LTX is considered as rescue therapy for ALF. TRMU-associated ALF has been first described in 13 individuals in 2009.[2] Subsequently, another 23 cases were described.[3-16]

This study now presented the largest reported cohort of 62 individuals with TRMU deficiency, summarizing the initial clinical presentations and long-term clinical course as well as all variants in TRMU associated with the disease. Still, cohort heterogeneity, sample size, and the retrospective nature of this study may limit the conclusions that can be drawn from the data analysis.

In translating our study results to practical, evidence-based recommendations, eg, when informing parents or setting up a treatment plan with the medical team for a newly diagnosed individual with TRMU deficiency, we can conclude that in most (40/62 = 65%) individuals, TRMU-associated ALF is indeed a transient, reversible disease. Unfortunately, however, it led to death in more than a third of the affected individuals. Presence of LoF variants was a negative predictor for overall individual survival (Figure 1D). Furthermore, in

Table 2 Detailed individual characteristics of all individuals with TRMU deficiency in this study

Patient	Alive	Cause of Death	Age at Death, mo	Age at First Symptoms, mo	Age at Diagnosis, mo	TRMU Variant 1 (NM_018006.5)	TRMU Variant 2 (NM_018006.5)	Age at Last Follow-up, mo	Hepatic Symptoms	No. of ALF Episodes	LTx	Supplementation	Failure to Thrive	Lactic Acidosis	Neuro developmental Delay	Neuro developmental Delay Resolved	Muscular Hypotonia	Growth Abnormality	Others	Reference
TRMU-01	Yes			7.5	108	c.589A>C p.(Lys197Gln)	c.1081C>T p.(Arg361Cys)	190	x	2	No	AA	x		x	Yes		x		
TRMU-02*	Yes			4	13	c.835G>A p.(Val279Met)	c.1041_1044del p.(Asn347LysfsTer7)	144	x	1	No	NAC								Grover et al[7]
TRMU-03*	No	RC	6	6	8	c.835G>A p.(Val279Met)	c.936G>A p.(Trp312Ter)	6	x	1	No	No	x							
TRMU-04	No	HF	4	1.25	6	c.835G>A p.(Val279Met)	c.1142G>A p.(Gly381Glu)	4	x	1	No	No			x	Deceased				
TRMU-05*	No	HF	8	0.1	pm	c.835G>A p.(Val279Met)	c.248+1G>A p.(?)	8	x	3	Yes	NAC	x					x		Gaignard et al[5]
TRMU-06	Yes			0.1	48	c.697C>T p.(Leu233Phe)	c.697C>T p.(Leu233Phe)	157	x	0	No	No	x				x	x		Gaignard et al[5]
TRMU-07	Yes			2	4	c.44T>G p.(Val15Gly)	c.44T>G p.(Val15Gly)	107	x	1	No	NAC, Sel	x	x	x	Yes				
TRMU-08	No	MOF	7	3	4	c.40G>A p.(Gly14Ser)	c.878C>T p.(Pro293Leu)	7	x	1	Yes	AA, NAC		x						
TRMU-09	Yes			8	32	c.1073_1081dup p.(Gln358_Val360dup)	c.1108G>A p.(Val370Met)	96	x	0	No	AA	x				x			
TRMU-10	No	MOF	0.1	0.1	pm	c.664T>G p.(Cys222Gly)	c.664T>G p.(Cys222Gly)	0.1	x	0	No	No	x	x						
TRMU-11	Yes			4	24	c.649G>A p.(Glu217Lys)	c.835G>A p.(Val279Met)	120	x	0	No	No	x	x				x		Gaignard et al[5]
TRMU-12*	Yes			1.5	26	c.1084G>A p.(Ala362Thr)	del 22q13.31 46730453–4,673,227	60	x	0	No	L-Cys, NAC	x	x	x	Yes		x		Murali et al[15]
TRMU-13*	Yes			6	Fetal	c.1084G>A p.(Ala362Thr)	del 22q13.31 46730453–4,673,227	27	x	0	No	L-Cys, NAC		x						Murali et al[15]
TRMU-14	Yes			2	2.5	c.246C>G p.(Phe82Leu)	c.525_527del p.(Phe176del)	53	x	1	Yes	NAC	x	x	x	No				Murali et al[15]
TRMU-15	No	HF	3	0.5	2.5	c.1142G>A p.(Gly381Glu)	c.37_48dup p.(G13_D16dup)	3	x	2	No	NAC	x	x			x		encephalopathy	Murali et al[15]
TRMU-16*	Yes			1.75	2.5	c.2T>C p.(Met1?)	c.2T>C p.(Met1?)	7.5	x	3	No	L-Cys, NAC		x	x	No		x	Encephalopathy	
TRMU-17	Yes			2	14	c.835G>A p.(Val279Met)	c.835G>A p.(Val279Met)	91	x	2	Yes	NAC	x		x	Yes		x		
TRMU-18*	No	MOF	2	1	pm	c.954dupC p.(Ala319ArgfsTer87)	c.954dup p.(Ala319ArgfsTer87)	2	x	0	No	No	x	x	x	Deceased		x	Cardiomyopathy	
TRMU-19	Yes			4	6	c.229T>C p.(Tyr77His)	c.229T>C p.(Tyr77His)	104	x	0	No	NAC	x		x	Yes	x	x		
TRMU-20	No	HF	3	2	pm	c.827C>T p.(Pro276Leu)	c.827C>T p.(Pro276Leu)	3	x	2	No	No	x					x		
TRMU-21	No	HF	3.5	0.1	pm	c.1005C>G p.(His335Gln)	c.1005C>G p.(His335Gln)	3.5	x	2	No	AA	x	x	x	Deceased	x			
TRMU-22	Yes			0.1	0.1	c.287A>G p.(Asn96Ser)	c.287A>G p.(Asn96Ser)	49	x	1	No	No	x	x	x	No	x			
TRMU-23	No	RC	1.75	1	pm	c.287A>G p.(Asn96Ser)	c.287A>G p.(Asn96Ser)	2	x	1	No	No	x	x	x	Deceased	x	x	Cardiomyopathy	
TRMU-24	Yes			2	NA	c.530T>A p.(Leu177His)	c.1073_1081dup p.(Gln358_Val360dup)	11	x	2	Yes	AA, L-Cys, NAC, Sel	x	x			x			
TRMU-25	Yes			3	0.1	c.835G>A p.(Val279Met)	c.835G>A p.(Val279Met)	72	x	1	No	NAC	x	x					Anemia, hyperechogenic kidneys	
TRMU-26	Yes			2	0.1	c.835G>A p.(Val279Met)	c.835G>A p.(Val279Met)	54	x	1	No	NAC	x							
TRMU-27	Yes			7.5	10	c.287A>G p.(Asn96Ser)	c.521C>T p.(Thr174Ile)	49	x	0	No	No			x	No	x			
TRMU-28*	Yes			2	5	c.835G>A p.(Val279Met)	c.954dup p.(Ala319ArgfsTer87)	77	x	3	Yes	No	x	x	x	Lost to follow-up				
TRMU-29*	Yes			3	6	c.835G>A p.(Val279Met)	c.835G>A p.(Val279Met)	96	x	1	Yes	No								
TRMU-30*	No	HF	2	0.25	1	c.117G>A p.(Trp39Ter)	c.680G>C p.(Arg227Thr)	2	x	1	No	No	x	x	x	Deceased		x	Encephalopathy, epileptic seizures	Soler-Alfonso et al,[11] Murali et al[15]
TRMU-31*	Yes			2	Fetal	c.117G>A p.(Trp39Ter)	c.680G>C p.(Arg227Thr)	45	x	1	No	AA, L-Cys, NAC, Sel		x	x	Lost to follow-up	x	x		Soler-Alfonso et al,[11] Murali et al[15]
TRMU-32*	Yes			4	17	c.711dup p.(Gln238AlafsTer14)	c.1073_1081dup p.(Gln358_Val360dup)	105	x	1	No	No			x					Schara et al[3]
TRMU-33	Yes			1	16	c.229T>C p.(Tyr77His)	c.229T>C p.(Tyr77His)	157	x	1	No	No	x		x	Yes	x	x		Zeharia et al[2]
TRMU-34	Yes			1.5	24	c.229T>C p.(Tyr77His)	c.229T>C p.(Tyr77His)	172	x	1	No	No	x	x	x	Yes	x	x		Zeharia et al[2]
TRMU-35	Yes			4	6	c.229T>C p.(Tyr77His)	c.229T>C p.(Tyr77His)	93	x	1	No	NAC	x	x	x	Yes	x	x	Lower limb edema	
TRMU-36	Yes			3	3	c.229T>C p.(Tyr77His)	c.229T>C p.(Tyr77His)	73	x	0	No	No	x					x		
TRMU-37	Yes			3	120	c.229T>C p.(Tyr77His)	c.229T>C p.(Tyr77His)	270	x	1	No	No	x						Cardiomyopathy	Zeharia et al[2]
TRMU-38	Yes			0.1	60	c.40G>A p.(Gly14Ser)	No maternal cDNA expression	204	x	5	No	No		x					Cardiomyopathy	Zeharia et al[2]
TRMU-39	Yes			0.1	1	c.653G>T p.(Ser218Ile)	c.1073_1081dup p.(Gln358_Val360dup)	40	x	1	No	No	x	x	x	Yes			Epileptic seizures	
TRMU-40*	No	Sepsis	3	0.1	pm	c.339T>G p.(Tyr113Ter)	c.646_648del p.(Lys216del)	3	x	1	No	No	x	x	x	Deceased				
TRMU-41	Yes			2	NA	c.653G>T p.(Ser218Ile)	c.1073_1081dup p.(Gln358_Val360dup)	161	x	5	Yes	AA	x	x	x	Yes			Hypothyroidism	
TRMU-42	Yes			2	7	c.383A>G p.(Tyr128Cys)	c.835G>A p.(Val279Met)	45	x	1	No	AA		x			x	x		Nicastro et al[10]

Table 2 Continued

Patient	Alive	Cause of Death	Age at Death, mo	Age at First Symptoms, mo	Age at Diagnosis, mo	TRMU Variant 1 (NM_018006.5)	TRMU Variant 2 (NM_018006.5)	Age at Last Follow-up, mo	Hepatic Symptoms	No. of ALF Episodes	LTx	Supplementation	Failure to Thrive	Lactic Acidosis	Neuro developmental Delay	Neuro developmental Delay Resolved	Muscular Hypotonia	Growth Abnormality	Others	Reference
TRMU-43	Yes			4	28	c.835G>A p.(Val279Met)	c.835G>A p.(Val279Met)	66	x	0	No	No		x	x	Yes			Microcephaly	Kose et al[14]
TRMU-44*	Yes			5	6	c.581del p.(Gly194AspfsTer2)	c.611C>T p.(Ala204Val)	17	x	1	Yes	NAC	x	x				x		
TRMU-45*	Yes			2	4.5	c.671T>G p.(Ile224Ser)	c.835G>A p.(Val279Met)	36	x	0	No	AA, L-Cys, NAC	x	x			x	x		
TRMU-46	No	MOF	1	0.1	pm	c.287A>G p.(Asn96Ser)	c.287A>G p.(Asn96Ser)	1	x	0	No	No	x	x	x	Deceased	x		Cardiomyopathy, encephalopathy	Taylor et al[6]
TRMU-47*	Yes			3	3	c.229T>C p.(Tyr77His)	c.706-1G>A p.(?)	49	x	1	Yes	NAC	x	x			x	x		
TRMU-48	Yes			2.5	78	c.229T>C p.(Tyr77His)	c.229T>C p.(Tyr77His)	223	x	1	Yes	NAC		x			x			
L-TRMU-49	No	MOF	4	3	NA	c.229T>C p.(Tyr77His)	c.706-1G>A p.(?)	4	x	1	No	No			x					Zeharia et al[2]
L-TRMU-50	Yes			4	NA	c.229T>C p.(Tyr77His)	c.229T>C p.(Tyr77His)	96	x	1	No	No			x					Zeharia et al[2]
L-TRMU-51	Yes			4	NA	c.229T>C p.(Tyr77His)	c.229T>C p.(Tyr77His)	168	x	1	No	No			x					Zeharia et al[2]
L-TRMU-52	Yes			6	NA	c.815G>A p.(Gly272Asp)	c.815G>A p.(Gly272Asp)	24	NA	NA	No	No			x					Zeharia et al[2]
L-TRMU-53*	No	MOF		1	NA	c.835G>A p.(Val279Met)	c.500–510del p.(Ala167GlufsTer36)	2	x	1	No	No			x					Zeharia et al[2]
L-TRMU-54*	No	MOF	3	0.1	NA	c.2T>A p.(Met1?)	c.2T>A p.(Met1?)	3	x	NA	No	No			x					Zeharia et al[2]
L-TRMU-55*	No	MOF	4	0.1	NA	c.2T>A p.(Met1?)	c.2T>A p.(Met1?)	4	x	1	No	No			x					Zeharia et al[2]
L-TRMU-56*	Yes			5	NA	c.835G>A p.(Val279Met)	c.1102-3C>G p.(?)	48	x	0	No	No			x		x		Bulbar involvment	Uusimaa et al[4]
L-TRMU-57*	No	RC	0.1	0.1	pm	c.34_35dup p.(Gly13ProfsTer13)	c244T>G p.(Phe82Val)	0.1	x	1	No	No	x	x			x			Qin et al[13]
L-TRMU-58*	No	HF	6	3	3	c.162_163del p.(Cys54Ter)	c.680G>C p.(Arg227Thr)	6	x	1	No	No	x	x	x	Deceased	x		Encephalopathy	Sala-Coromina et al[16]
L-TRMU-59*	No	HF	1	0.1	1	c.2T>A p.(Met1?)	c.491del p.(Leu164ProfsTer22)	1	x	1	No	No	x	x	x	Deceased	x		Encephalopathy	Sala-Coromina et al[16]
L-TRMU-60	Yes			3	9	c.304A>C p.(Asn102Asp)	c.835G>A p.(Val279Met)	60	x	1	No	No	x	x	x	Yes		x	Ichtyosis	Indolfi et al[8]
L-TRMU-61	Yes			4	NA	c.229T>C p.(Tyr77His)	c.229T>C p.(Tyr77His)	NA	x	1	No	No			x				Anemia, hypothyroidism, microcephaly	Gil-Margolis et al[9]
L-TRMU-62	Yes			5	NA	c.229T>C p.(Tyr77His)	c.229T>C p.(Tyr77His)	NA	x	1	No	No			x				Anemia, hypothyroidism, microcephaly	Gil-Margolis et al[9]

Unpublished individuals are presented in bold. Loss of function variants are marked with an asterisk. L-TRMU nomenclature reflects cases with only published data available. The following reference numbers were used for all variants: NM_018006.5, NP_060476.2 and NC_000022.11.

AA, ascorbic acid; ALF, acute liver failure; cDNA, complementary DNA; HF, hepatic failure; L-cys, L-cysteine; LTx, liver transplantation; MOF, multiorgan failure; NA, not available; NAC, N-acetylcysteine; pm, post mortem; RC, respiratory and circulatory failure; Sel, selenium; x, applicable/yes.

A

B

C

D

E

Figure 1   Genetics and clinical findings. A. All *TRMU* variants reported in this study are indicated by black lines above the corresponding amino acid position. TRMU protein domains and regions of important protein function are highlighted. B. Density plot of the frequency of *TRMU* variants reported in this study with respect to the affected protein domains. C. In silico pathogenicity prediction for all potential *TRMU* missense variants using REVEL score. D. LoF variants (red) influence survival probability of individuals with TRMU deficiency in comparison with Kaplan-Meier estimator. E. Most prevalent clinical symptoms of the study cohort using Human Phenotype Ontology terminology. These include the following presentations: liver failure, cholestasis, and jaundice (abnormality of the liver); lactic acidosis; failure to thrive (abnormality of body weight), vomiting and diarrhea (abdominal symptom); motor delay, neurodevelopmental delay, and encephalopathy (abnormality of the nervous system); hypotonia (muscular hypotonia); and growth retardation (growth abnormality). ATP, adenosine triphosphate; LoF, loss of function; REVEL, Rare Exome Variant Ensemble Learner; tRNA, transfer RNA.

Figure 2   Individual survival and hepatic phenotype. A. Supplementation therapy (red) influences survival probability of individuals with TRMU deficiency in comparison with Kaplan-Meier estimator. B. Cause of death for the 14 deceased individuals with TRMU deficiency. C. Most common features of the hepatic presentation of individuals with TRMU deficiency. D. Density plot indicating the occurrence of ALF episodes over the first 15 months of life. E. Frequency of ALF episodes per individual across the cohort. F. Survival probability of individuals with TRMU deficiency with LTX (red) and without (blue) LTX therapy is compared using Kaplan-Meier estimator. ALF, acute liver failure; LTX, liver transplantation; suppl, supplementation.

Figure 3   Native liver survival, liver histology, clinical presentation, and course of TRMU-related symptoms. A. Supplementation therapy (blue) does not influence native liver survival, eg, the need for liver transplantation, in comparison with Kaplan-Meier estimator. B. Most prevalent findings in liver histopathology. C. Common clinical presentation in individuals with TRMU deficiency besides hepatic symptoms. D. Course of individuals with neurodevelopmental delay over time. Note, that 1 individual was lost to follow-up. E. Less common clinical findings in individuals with TRMU deficiency.

this cohort, no episodes of ALF occurred after the first year of life.

A possible explanation for this temporal presentation of ALF was provided recently by the demonstration that over the first year of life, some mitochondrial defects (including TRMU) can be metabolically compensated for by the activation of the cellular stress response and mTOR-associated mitochondrial biogenesis.[27] This would support the hypothesis of cysteine supplementation therapy, which has shown benefits in anecdotal cases of TRMU disease.[11,15] Indeed, we found that supplementation with at least 1 cysteine source, NAC being the most frequently used in our cohort, improved survival significantly (level of evidence 1c, Figure 2A, survival probability in the first year with supplementation 90%, without 50%), particularly in the subgroup of individuals with predicted loss of protein function.

Consequently, it is an evidence-based medicine level 1c recommendation to supplement with a cysteine source in any patient with TRMU deficiency at least in the first year. We further recommend considering NAC as the primary cysteine source, given that it is thought to provide extended benefits for failing liver tissue by compensating for redox dysfunction (as commonly used in paracetamol-induced liver failure). We would further encourage consideration of supplementing NAC to all cases of suspected mitochondrial liver failure until TRMU-related disease has been excluded. However, conclusions on which cysteine source is the best and dosing and duration of supplementation cannot be drawn owing to the limited data availability. Further research is required to better understand the underlying pathophysiology and possible treatment options.

On theoretical grounds, supplementation may only be necessary up to age 1 year. Interestingly, native liver survival (Figure 2F) seems unaffected by supplementation and the occurrence of ALF under supplementation may still require LTX, because once the catastrophic cascade of hepatic necrosis is initiated, it seems not to be ameliorated by adding a cysteine sources. One could speculate that an earlier diagnosis and a consecutively early cysteine supplementation might improve outcome. We cannot arrive to a final conclusion based on our limited data. However, the survival of 2 individuals diagnosed prenatally who received early supplementation with cysteine suggests that this approach may lead to a better outcome.

The decisions regarding necessity and timing of LTX remain specific to the clinical circumstances; however, the fact that no ALF was reported after age 1 year should be considered. Alternatively, progression of established ALF and worsening of hepatic encephalopathy with associated cerebral injury will eventually necessitate LTX.

TRMU deficiency is predominantly a disease of the first year of life. Our cohort yielded multiorgan involvements but only in a minority of patients (Figure 3E). However, the most commonly reported during follow-up in our cohort was neurodevelopmental delay. It is impossible to determine to what extent the neurodevelopmental delay is secondary to

the liver failure or an unrelated clinical expression of mitochondrial disease. This also holds for the brain magnetic resonance imaging finding of bilateral hyperintensities in the basal ganglia as described in the study by Sala-Coromina et al.[16] These were reported during ALF in 2 patients who died shortly afterward. Hence, it is impossible to ascertain that this magnetic resonance imaging finding reflects the imaging of a vulnerable brain with mitochondrial dysfunction or whether this child would have progressed to the full picture of Leigh syndrome (subacute necrotizing encephalomyelopathy) in the strictest sense.[28]

TRMU deficiency was shown to have a specific clinical phenotype of an infantile onset (when survived) reversible, isolated ALF and can be distinguished from its differential diagnoses that encompass several other IMDs. In contrast to TRMU deficiency, individuals with DGUOK deficiency often already have liver cirrhosis upon presentation and do not show a reversible phenotype. In individuals with NBAS deficiency, the reversible ALF periods are related to febrile infections.[29] Individuals with LARS1 deficiency are characterized by recurrent elevation of liver transaminases up to liver failure and multisystem involvement (abnormalities of growth, blood, nervous system, muscles).[25] Furthermore, biallelic RINT1 variants have been associated with infantile ALF in association again with multisystem involvement in 1 family.[30]

Given the rarity of TRMU deficiency, we generally advise that there should be careful follow-up of individuals in the first year by an experienced team at a specialized center with pediatric liver and mitochondrial disease specialists. Extended but regular follow-up visits with ultrasound examination of the liver and biochemical surveillance, including alpha-fetoprotein levels, should also exceed the first year of life. Furthermore, we suggest that, where clinically and genetically indicated, active consideration of LTX seems advisable.

Data Availability

Data will be supplied by the authors upon request.

Acknowledgments

Funding

Author Information

Conceptualization: G.F.V., S.W.; Data Curation: G.F.V., S.W., Y.M.-G., Y.E.L., R.G.F., J.A.M., H.B., L.D.S., H.Pe., A.Pen., F.S.A., J.J.B., G.B., I.B., N.B., B.B., J.C., E.C., D.C., A.M.D., N.D., A.D.M., F.D., E.A.E., M.E., M.Ke., M.Ko., A.K., D.L., R.M., M.G.M., K.Mo., T.M., K.Mu., E.N., A.Pec., H.Pr., D.P.-A., A.R., R.S., F.S., M.Sc., M.Shag., M.Shar., C.S.-A., C.S., I.S., M.St., R.W.T., D.R.T., E.L.T., J.-S.W., D.W.; Methodology: G.F.V., S.W., R.G.F., J.A.M.; Visualization: G.F.V., S.W., H.B., J.S.;

Writing-original draft: G.F.V., S.W.; Writing-review and editing: G.F.V., S.W., Y.M.-G., Y.E.L., R.G.F., J.A.M., H.B., L.D.S., H.Pe., H.Pr., A.Pen., F.S.A., J.J.B., G.B., I.B., N.B., B.B., J.C., E.C., D.C., A.M.D., N.D., A.D.M., F.D., E.A.E., M.E., M.Ke., M.Ko., A.K., D.L., R.M., M.G.M., K.Mo., T.M., K.Mu., E.N., A.Pec., H.Pe., H.Pr., D.P.-A., A.R., R.S., F.S., M.Sc., M.Shag., M.Shar., C.S.-A., C.S., I.S., M.St., R.W.T., D.R.T., E.L.T., J.-S.W., D.W.

Ethics Declaration

This study was conducted in accordance with the guidelines of the Institutional Review Board of the Medical University of Innsbruck and the 1975 Declaration of Helsinki.[31] Participants gave written informed consent for genetic investigations according to local regulations.

Conflict of Interest

The authors declare no conflicts of interest.

Additional Information

The online version of this article (https://doi.org/10.1016/j.gim.2022.09.015) contains supplementary material, which is available to authorized users.

Authors

Georg F. Vogel[1,2,*] [iD], Yael Mozer-Glassberg[3], Yuval E. Landau[4,5], Lea D. Schlieben[6,7], Holger Prokisch[6,7], René G. Feichtinger[8], Johannes A. Mayr[8], Heiko Brennenstuhl[9,10], Julian Schröter[11], Agnes Pechlaner[1], Fowzan S. Alkuraya[12], Joshua J. Baker[13], Giulia Barcia[14,15], Ivo Baric[16], Nancy Braverman[17], Birute Burnyte[18], John Christodoulou[19,20], Elzbieta Ciara[21], David Coman[22], Anibh M. Das[23], Niklas Darin[24], Adela Della Marina[25], Felix Distelmaier[26], Erik A. Eklund[27], Melike Ersoy[28], Weiyan Fang[29], Pauline Gaignard[30], Rebecca D. Ganetzky[31,32], Emmanuel Gonzales[33,34], Caoimhe Howard[35], Joanne Hughes[35], Vassiliki Konstantopoulou[36], Melis Kose[37,38], Marina Kerr[39], Aneal Khan[39], Dominic Lenz[9], Robert McFarland[40,41], Merav Gil Margolis[42], Kevin Morrison[43], Thomas Müller[1], Kei Murayama[44], Emanuele Nicastro[45], Alessandra Pennisi[14,15], Heidi Peters[46], Dorota Piekutowska-Abramczuk[21], Agnès Rötig[15], René Santer[47], Fernando Scaglia[48,49,50], Manuel Schiff[14,15,51], Mohmmad Shagrani[52,53], Mark Sharrard[54], Claudia Soler-Alfonso[48],

Christian Staufner[9], Imogen Storey[55], Michael Stormon[56], Robert W. Taylor[40,41], David R. Thorburn[19,20], Elisa Leao Teles[57], Jian-She Wang[29], Daniel Weghuber[8], Saskia Wortmann[8,58]

Affiliations

[1]Department of Paediatrics I, Medical University of Innsbruck, Innsbruck, Austria; [2]Institute of Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria; [3]Institute for Gastroenterology, Nutrition and Liver diseases, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel; [4]Metabolism Service, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel; [5]Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; [6]Institute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany; [7]Institute of Neurogenomics, Computational Health Center, Helmholtz Zentrum München, Neuherberg, Germany; [8]University Children's Hospital, Salzburger Landeskliniken and Paracelsus Medical University, Salzburg, Austria; [9]Division of Neuropaediatrics and Metabolic Medicine, Center for Paediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany; [10]Institute of Human Genetics, Heidelberg University, Heidelberg, Germany; [11]Division of Paediatric Epileptology, Center for Paediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany; [12]Department of Genetics, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; [13]Division of Genetics, Birth Defects and Metabolism, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; [14]Department of Medical Genetics and Reference Center for Mitochondrial Diseases (CARAMMEL), Necker Hospital, Université Paris Cité, Paris, France; [15]Institut Imagine, INSERM UMR 1163, Paris, France; [16]Department of Pediatrics, School of Medicine, University Hospital Center Zagreb and University of Zagreb, Zagreb, Croatia; [17]Division of Medical Genetics, Department of Pediatrics and Human Genetics, McGill University, Montreal, Quebec, Canada; [18]Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; [19]Brain and Mitochondrial Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia; [20]Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia; [21]Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland; [22]Faculty of Medicine, Queensland Children's Hospital, University of Queensland, Herston, Brisbane, Queensland, Australia; [23]Department of Paediatrics, Paediatric Metabolic Medicine, Hannover Medical School, Hannover, Germany; [24]Department of Pediatrics, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden; [25]Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- und Behavioral Sciences, University Duisburg-Essen, Essen, Germany; [26]Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany; [27]Section for Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden; [28]Department of Pediatrics, Division of Pediatric Metabolism, University of Health Sciences, Bakırkoy Dr. Sadi Konuk Training and Research, Istanbul, Turkey; [29]The Center for Pediatric Liver Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China; [30]Department of Biochemistry, Reference Center for Mitochondrial Disease, FILNEMUS, Bicêtre University Hospital, University of Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, Paris, France; [31]Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; [32]Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; [33]Pediatric Hepatology and Pediatric Liver Transplantation Unit, Reference Center for Mitochondrial Disease, FILNEMUS, Bicêtre University Hospital, University of Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, Paris, France; [34]Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, Paris, France; [35]Children's Health Ireland, Temple Street Hospital, Dublin, Ireland; [36]Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria; [37]Division of Inborn Errors of Metabolism, Department of Pediatrics, İzmir Katip Çelebi University, Izmir, Turkey; [38]Division of Genetics, Department of Pediatrics, Ege University, Izmir, Turkey; [39]Discovery DNA, Metabolics and Genetics in Canada (M.A.G.I.C.) Clinic Ltd, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; [40]Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom; [41]NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; [42]Institute of Endocrinology and Diabetes, National Center of Childhood Diabetes Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel; [43]Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; [44]Department of Metabolism, Chiba Children's Hospital, Midori-ku, Chiba, Japan; [45]Pediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII, Bergamo, Italy; [46]Department of Metabolic Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia; [47]Department of Pediatrics, University Medical Center Hamburg Eppendorf, Hamburg, Germany; [48]Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; [49]Texas Children's Hospital, Houston,

TX; [50]Joint BCM-CUHK Center of Medical Genetics, Prince of Wales Hospital, Shatin, Hong Kong SAR; [51]Reference Center of Inherited Metabolic Disorders, Necker Hospital, Université Paris Cité, Paris, France; [52]Department of Liver & Small Bowel Health Centre King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; [53]College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; [54]Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom; [55]University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; [56]Department of Gastroenterology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; [57]Inherited Metabolic Diseases Reference Centre, São João Hospital University Centre, EPE, Porto, Portugal; [58]Amalia Children's Hospital, Radboudumc, Nijmegen, The Netherlands

References

1. Narkewicz MR, Horslen S, Hardison RM, et al. A learning collaborative approach increases specificity of diagnosis of acute liver failure in pediatric patients. *Clin Gastroenterol Hepatol*. 2018;16(11):1801-1810.e3. http://doi.org/10.1016/j.cgh.2018.04.050

2. Zeharia A, Shaag A, Pappo O, et al. Acute infantile liver failure due to mutations in the TRMU gene. *Am J Hum Genet*. 2009;85(3):401-407. Published correction appears in *Am J Hum Genet*. 2010;86(2):295. https://doi.org/10.1016/j.ajhg.2009.08.004

3. Schara U, von Kleist-Retzow JC, Lainka E, et al. Acute liver failure with subsequent cirrhosis as the primary manifestation of TRMU mutations. *J Inherit Metab Dis*. 2011;34(1):197-201. http://doi.org/10.1007/s10545-010-9250-z

4. Uusimaa J, Jungbluth H, Fratter C, et al. Reversible infantile respiratory chain deficiency is a unique, genetically heterogenous mitochondrial disease. *J Med Genet*. 2011;48(10):660-668. http://doi.org/10.1136/jmg.2011.089995

5. Gaignard P, Gonzales E, Ackermann O, et al. Mitochondrial infantile liver disease due to TRMU gene mutations: three new cases. *JIMD Rep*. 2013;11:117-123. http://doi.org/10.1007/8904_2013_230

6. Taylor RW, Pyle A, Griffin H, et al. Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. *JAMA*. 2014;312(1):68-77. http://doi.org/10.1001/jama.2014.7184

7. Grover Z, Lewindon P, Clousten A, Shaag A, Elpeleg O, Coman D. Hepatic copper accumulation: a novel feature in transient infantile liver failure due to TRMU mutations? *JIMD Rep*. 2015;21:109-113. http://doi.org/10.1007/8904_2014_402

8. Indolfi G, Iascone M, Remaschi G, et al. A child with ichthyosis and liver failure. *J Pediatr Gastroenterol Nutr*. 2017;65(3):e70-e73. http://doi.org/10.1097/MPG.0000000000001645

9. Gil-Margolis M, Mozer-Glassberg Y, Tobar A, Ashkenazi S, Zeharia A, Marom D. [TRMU mutations – reversible infantile liver failure or multisystem disorder?]. *Harefuah*. 2018;157(1):52-57.

10. Nicastro E, Di Giorgio A, Marchetti D, et al. Diagnostic yield of an algorithm for neonatal and infantile cholestasis integrating next-generation sequencing. *J Pediatr*. 2019;211:54-62.e4. http://doi.org/10.1016/j.jpeds.2019.04.016

11. Soler-Alfonso C, Pillai N, Cooney E, Mysore KR, Boyer S, Scaglia F. L-cysteine supplementation prevents liver transplantation in a patient with TRMU deficiency. *Mol Genet Metab Rep*. 2019;19:100453. http://doi.org/10.1016/j.ymgmr.2019.100453

12. Kerr M, Hume S, Omar F, et al. MITO-FIND: A study in 390 patients to determine a diagnostic strategy for mitochondrial disease. *Mol Genet Metab*. 2020;131(1-2):66-82. http://doi.org/10.1016/j.ymgme.2020.08.009

13. Qin Z, Yang Q, Yi S, Huang L, Shen Y, Luo J. Whole-exome sequencing identified novel compound heterozygous variants in a Chinese neonate with liver failure and review of literature. *Mol Genet Genomic Med*. 2020;8(12):e1515. http://doi.org/10.1002/mgg3.1515

14. Kose M, Isik E, Aykut A, et al. The utility of next-generation sequencing technologies in diagnosis of Mendelian mitochondrial diseases and reflections on clinical spectrum. *J Pediatr Endocrinol Metab*. 2021;34(4):417-430. http://doi.org/10.1515/jpem-2020-0410

15. Murali CN, Soler-Alfonso C, Loomes KM, et al. TRMU deficiency: A broad clinical spectrum responsive to cysteine supplementation. *Mol Genet Metab*. 2021;132(2):146-153. http://doi.org/10.1016/j.ymgme.2021.01.005

16. Sala-Coromina J, Miguel LD, de Las Heras J, et al. Leigh syndrome associated with TRMU gene mutations. *Mol Genet Metab Rep*. 2020;26:100690. http://doi.org/10.1016/j.ymgmr.2020.100690

17. Sturman JA, Gaull G, Raiha NC. Absence of cystathionase in human fetal liver: is cystine essential? *Science*. 1970;169(3940):74-76. http://doi.org/10.1126/science.169.3940.74

18. Ferreira CR, Rahman S, Keller M, Zschocke J, ICIMD Advisory Group. An international classification of inherited metabolic disorders (ICIMD). *J Inherit Metab Dis*. 2021;44(1):164-177. http://doi.org/10.1002/jimd.12348

19. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424. http://doi.org/10.1038/gim.2015.30

20. Köhler S, Gargano M, Matentzoglu N, et al. The Human Phenotype Ontology in 2021. *Nucleic Acids Res*. 2021;49(D1):D1207-D1217. http://doi.org/10.1093/nar/gkaa1043

21. Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: an Ensemble method for predicting the pathogenicity of rare missense variants. *Am J Hum Genet*. 2016;99(4):877-885. http://doi.org/10.1016/j.ajhg.2016.08.016

22. Jagadeesh KA, Wenger AM, Berger MJ, et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. *Nat Genet*. 2016;48(12):1581-1586. http://doi.org/10.1038/ng.3703

23. Vaser R, Adusumalli S, Leng SN, Sikic M, Ng PC. SIFT missense predictions for genomes. *Nat Protoc*. 2016;11(1):1-9. http://doi.org/10.1038/nprot.2015.123

24. Hebebrand M, Hüffmeier U, Trollmann R, et al. The mutational and phenotypic spectrum of TUBA1A-associated tubulinopathy. *Orphanet J Rare Dis*. 2019;14(1):38. http://doi.org/10.1186/s13023-019-1020-x

25. Lenz D, Smith DEC, Crushell E, et al. Genotypic diversity and phenotypic spectrum of infantile liver failure syndrome type 1 due to variants in LARS1. *Genet Med*. 2020;22(11):1863-1873. http://doi.org/10.1038/s41436-020-0904-4

26. Squires JE, Alonso EM, Ibrahim SH, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the diagnosis and management of pediatric acute liver failure. *J Pediatr Gastroenterol Nutr*. 2022;74(1):138-158. http://doi.org/10.1097/MPG.0000000000003268

27. Hathazi D, Griffin H, Jennings MJ, et al. Metabolic shift underlies recovery in reversible infantile respiratory chain deficiency. *EMBO J*. 2020;39(23):e105364. http://doi.org/10.15252/embj.2020105364

28. Rahman S, Thorburn D. Nuclear gene-encoded Leigh syndrome spectrum overview. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews [Internet]*. University of Washington, Seattle; 1993–2022.

29. Staufner C, Peters B, Wagner M, et al. Defining clinical subgroups and genotype-phenotype correlations in NBAS-associated disease across 110 patients. *Genet Med*. 2020;22:610-621. http://doi.org/10.1038/s41436-019-0698-4

30. Cousin MA, Conboy E, Wang JS, et al. RINT1 Bi-allelic variations cause infantile-onset recurrent acute liver failure and skeletal abnormalities. *Am J Hum Genet*. 2019;105:108-121. http://doi.org/10.1016/j.ajhg.2019.05.011

31. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191-2194. http://doi.org/10.1001/jama.2013.281053